Oncology & Cancer

Combining CAR-T cells and inhibitor drugs for high-risk neuroblastoma

Chimeric antigen receptor (CAR)-T cell therapy is a potent emerging weapon against cancer, altering patients' T cells so they can better find and destroy tumor cells. But CAR-T cell therapy doesn't work well in every cancer—including ...

Diseases, Conditions, Syndromes

Sickle cell and COVID-19: A risky mix of two diseases

UdeM's Stéphanie Forté and co-researchers in Canada and Brazil have shown how people with sickle cell disease or sickle cell trait have a higher chance of dying from COVID-19 than the general population.

Medications

New cell-based immunotherapy offered for melanoma

Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.

page 15 from 40